Overview

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Status:
Completed

Trial end date:
2020-02-25

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia and established CVD or at a high risk for CVD.

Phase:

Phase 2

Details

Lead Sponsor:

Akcea Therapeutics

Collaborator:

Ionis Pharmaceuticals, Inc.